Treatment News : Four in Five People With HIV and Hep C on Faldaprevir Achieve Early Treatment Success

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » March 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

March 6, 2013

Four in Five People With HIV and Hep C on Faldaprevir Achieve Early Treatment Success

CROI 2013Interim results from a trial of the hepatitis C virus (HCV) protease inhibitor faldaprevir, given to people coinfected with hep C and HIV, have shown an 80 percent early success rate. However, there have also been three deaths, composing 1 percent of the study cohort. Boehringer Ingelheim announced these findings of its Phase III clinical trail at the 20th annual Conference on Retroviruses and Opportunistic Infections (CROI) in Atlanta. Called STARTVerso 4, this trial is an open-label, sponsor-blinded study to assess the efficacy and safety of faldaprevir in combination with pegylated interferon and ribavirin.

The study included 308 coinfected participants who, at the study outset, were either treatment-naive or had experienced a relapse following previous hep C therapy with pegylated interferon and ribavirin. Some of the study volunteers were taking antiretrovirals (ARVs) for HIV, while others were treatment-naive. Seventeen percent of the cohort had cirrhosis.

The cohort was divided into two groups: One received either 12 or 24 weeks of a 240 mg daily dose of faldaprevir; the second group received 24 weeks of a 120 mg daily dose of faldaprevir. Both groups also received either 24 or 48 weeks of pegylated interferon and ribavirin.

After 12 weeks of treatment, 84 percent of the participants across both groups had achieved an undetectable hep C viral load. The study investigators qualified 80 percent of the group as achieving early treatment success, a result that was consistent regardless of prior hep C treatment status or HIV therapy. Those who achieved early success were qualified for randomization into a shortened course of treatment, cutting its duration from 48 to 24 weeks.

Among the most frequent adverse events were nausea (37 percent), fatigue (33 percent), diarrhea (27 percent), headache (23 percent) and weakness (22 percent). Thirty-two participants (10 percent) experienced serious adverse events; three of the patients died during the study. Thus far, 18 patients have left the study because of adverse events.

All the patients maintained HIV viral suppression throughout the study.

In a separate presentation at CROI, Boehringer Ingelheim also presented results from three open-label Phase I studies of drug-drug interactions of faldaprevir with the HIV medications boosted Prezista (darunavir/ritonavir), Sustiva (efavirenz) and Viread (tenofovir). The studies found faldaprevir did not significantly affect the way the body processes those ARVs.

To read the Boehringer Ingelheim release, click here.

Search: faldaprevir, coinfected, Boehringer Ingelheim, 20th annual Conference on Retroviruses and Opportunistic Infections, CROI, STARTVerso 4, pegylated interferon, ribavirin, Prezista, darunavir/ritonavir, Sustiva, efavirenz, Viread, tenofovir.


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
Starting Treatment
Search for the Cure
POZ Stories
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar


    Hillcrester
    Ramona
    California


    soy_Ric
    Rochester
    New York


    pevans
    San Francisco
    California


    clintonjrsyr
    syracuse
    New York
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Can social media help stop HIV stigma?
Yes
No

Survey
Mind Matters

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.